Adults subjects with advanced malignant pleural (cohort A) or peritoneal (cohorts B1 and B2) mesothelioma.
Conditions
Brief summary
Non-progression proportion 6 months after starting talazoparib in TALAMESO trial.
Detailed description
Related to progression free-survival based on RECIST 1.1 criteria (only for Malignant Peritoneal Mesothelioma), Related to progression free-survival based on mRECIST criteria (For Malignant Peritoneal Mesothelioma and Malignant Pleural Mesothelioma), Related to overall survival, Related to safety, Translational endpoints : On FFPE (paraffin embedded archival blocks) pretreatment tumor samples : BAP1 and HR genes status, Translational endpoints : On FFPE (paraffin embedded archival blocks) pretreatment tumor samples : RAD51 foci assay, Translational endpoints : On FFPE (paraffin embedded archival blocks) pretreatment tumor samples : HRD transcriptomic signature
Interventions
Sponsors
Hospices Civils De Lyon
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Non-progression proportion 6 months after starting talazoparib in TALAMESO trial. | — |
Secondary
| Measure | Time frame |
|---|---|
| Related to progression free-survival based on RECIST 1.1 criteria (only for Malignant Peritoneal Mesothelioma), Related to progression free-survival based on mRECIST criteria (For Malignant Peritoneal Mesothelioma and Malignant Pleural Mesothelioma), Related to overall survival, Related to safety, Translational endpoints : On FFPE (paraffin embedded archival blocks) pretreatment tumor samples : BAP1 and HR genes status, Translational endpoints : On FFPE (paraffin embedded archival blocks) pretreatment tumor samples : RAD51 foci assay, Translational endpoints : On FFPE (paraffin embedded archival blocks) pretreatment tumor samples : HRD transcriptomic signature | — |
Countries
France
Outcome results
None listed